<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03706547</url>
  </required_header>
  <id_info>
    <org_study_id>SHZS-MM002</org_study_id>
    <nct_id>NCT03706547</nct_id>
  </id_info>
  <brief_title>Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM</brief_title>
  <official_title>Clinical Study of Anti-CD19/BCMA Bispecific Chimeric Antigen Receptors (CARs) T Cell Therapy for Relapsed and Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peng Liu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hrain Biotechnology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai East Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to study the feasibility and efficacy of anti-CD19/BCMA
      bispecific chimeric antigen receptors (CARs) T cell therapy for relapsed and refractory
      multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives

      1. To determine the feasibility ad safety of anti-CD19/BCMA CAR-T cells in treating patients
      with BCMA-positive multiple myeloma.

      Secondary Objectives

        1. To access the efficacy of anti-CD19/BCMA CAR-T cells in patients with multiple myeloma.

        2. To determine in vivo dynamics and persistency of anti-CD19/BCMA CAR-T cells.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0</measure>
    <time_frame>6 months</time_frame>
    <description>Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall remission rate defined by the standard response criteria for myeloma for each arm</measure>
    <time_frame>8 weeks</time_frame>
    <description>Overall remission rate defined by the standard response criteria for myeloma for each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of CAR-positive T cells in circulation</measure>
    <time_frame>6 months</time_frame>
    <description>Duration of CAR-positive T cells in circulation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Multiple Myeloma in Relapse</condition>
  <condition>Multiple Myeloma Progression</condition>
  <arm_group>
    <arm_group_label>anti-CD19/BCMA CAR-T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy with a classic combination with fludarabine and cyclophosphamide;
Administration with anti-CD19/BCMA CAR-T cells in the BCMA-positive multiple myeloma patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-CD19/BCMA CAR-T cells</intervention_name>
    <description>Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs</description>
    <arm_group_label>anti-CD19/BCMA CAR-T cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30mg/m2/d</description>
    <arm_group_label>anti-CD19/BCMA CAR-T cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>300mg/m2/d</description>
    <arm_group_label>anti-CD19/BCMA CAR-T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Expected survival &gt; 12 weeks

          -  Diagnosis of Multiple Myeloma by IMWG updated criteria (2014)

          -  Pathology demonstrated that BCMA-poitive malignant plasma cells exited in bone marrow
             or plamacytoma

          -  Exited measurable lesions and in accordance with one of the following test indicators:
             serum M protein≥1 g/dl; urine M protein≥200 mg/24h; serum free light chain≥10 mg/dl;
             diagnosis of plasmacytoma by biopsy

          -  The criteria for relapsed and refractory multiple myeloma: patients previously
             received at least 3 different prior treatment regimens for multiple myeloma, including
             protein inhibitors (eg: Bortezomib), and immunomodulator (eg: Revlimid), and have
             disease progression in the past 60 days

          -  At least 90 days after stem cell transplantation

          -  Clinical performance status of ECOG score 0-2

          -  Creatinine≤2.0 mg/dl

          -  Bilirubin≤2.0 mg/dl

          -  The ALT/AST value is lower than 2.5-fold of normal value

          -  Accessible to intravenous injection, and no white blood cell collection
             contraindications

          -  Sexually active patients must be willing to utilize one of the more effective birth
             control methods for 30 days after the CTL infusion. Male partner should use a condom

          -  5mg/day dose of Prednisone or other equivalent steroid hormone drugs (eg:
             Dexamethasone) were not used for two weeks before apheresis and CAR-T infusion

          -  Able to understand and sign the Informed Consent Document.

        Exclusion Criteria:

          -  Patients with symptoms of central nervous system

          -  Patients with second malignancies in addition to multiple myeloma

          -  Active hepatitis B or C, HIV infections

          -  Any other active diseases could affect the enrollment of this trial

          -  Long term use of immunosuppressive agents after organ transplantation, except
             currently receiving or recently received glucocorticoid treatment

          -  Patients with organ failure

          -  Women of child-bearing potential who are pregnant or breastfeeding during therapy, or
             have a planned pregnancy with 2 months after therapy

          -  A history of mental illness and poorly controlled

          -  Women of child-bearing potential who are not willing to practice birth control from
             the time of enrollment on this study and for 2 months after receiving the preparative
             regimen. Women of child bearing potential must have a negative serum or urine
             pregnancy test performed within 48 hours before infusion

          -  Patients who are accounted by researchers to be not appropriate for this test

          -  Subjects suffering disease affects the understanding of informed consent or complying
             with study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peng Liu, M.D. &amp; Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zheng Wei, M.D.</last_name>
    <phone>+(86)-21 64041990</phone>
    <phone_ext>2925</phone_ext>
    <email>wei.zheng@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Hematology ,Fudan University Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.</citation>
    <PMID>29313949</PMID>
  </reference>
  <reference>
    <citation>Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ; Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003 May 8;348(19):1875-83.</citation>
    <PMID>12736280</PMID>
  </reference>
  <reference>
    <citation>Hari PN, McCarthy PL. Multiple myeloma: future directions in autologous transplantation and novel agents. Biol Blood Marrow Transplant. 2013 Jan;19(1 Suppl):S20-5. doi: 10.1016/j.bbmt.2012.11.002. Review.</citation>
    <PMID>23290439</PMID>
  </reference>
  <reference>
    <citation>Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, Giaccone L, Sorasio R, Omedè P, Baldi I, Bringhen S, Massaia M, Aglietta M, Levis A, Gallamini A, Fanin R, Palumbo A, Storb R, Ciccone G, Boccadoro M. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007 Mar 15;356(11):1110-20.</citation>
    <PMID>17360989</PMID>
  </reference>
  <reference>
    <citation>Hideshima T, Podar K, Chauhan D, Ishitsuka K, Mitsiades C, Tai YT, Hamasaki M, Raje N, Hideshima H, Schreiner G, Nguyen AN, Navas T, Munshi NC, Richardson PG, Higgins LS, Anderson KC. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene. 2004 Nov 18;23(54):8766-76.</citation>
    <PMID>15480425</PMID>
  </reference>
  <reference>
    <citation>Shringarpure R, Catley L, Bhole D, Burger R, Podar K, Tai YT, Kessler B, Galardy P, Ploegh H, Tassone P, Hideshima T, Mitsiades C, Munshi NC, Chauhan D, Anderson KC. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol. 2006 Jul;134(2):145-56.</citation>
    <PMID>16846475</PMID>
  </reference>
  <reference>
    <citation>Godfrey J, Benson DM Jr. The role of natural killer cells in immunity against multiple myeloma. Leuk Lymphoma. 2012 Sep;53(9):1666-76. doi: 10.3109/10428194.2012.676175. Epub 2012 Apr 19. Review.</citation>
    <PMID>22423650</PMID>
  </reference>
  <reference>
    <citation>Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol. 2011 Oct 25;11(11):750-61. doi: 10.1038/nri3088. Review.</citation>
    <PMID>22025054</PMID>
  </reference>
  <reference>
    <citation>Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B, Fogli M, Ferri E, Della Cuna GR, Tura S, Baccarani M, Lemoli RM. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood. 2002 Jul 1;100(1):230-7.</citation>
    <PMID>12070032</PMID>
  </reference>
  <reference>
    <citation>Favaloro J, Brown R, Aklilu E, Yang S, Suen H, Hart D, Fromm P, Gibson J, Khoo L, Ho PJ, Joshua D. Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. Leuk Lymphoma. 2014 May;55(5):1090-8. doi: 10.3109/10428194.2013.825905. Epub 2013 Aug 28.</citation>
    <PMID>23865833</PMID>
  </reference>
  <reference>
    <citation>Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015 Apr 3;348(6230):62-8. doi: 10.1126/science.aaa4967. Review.</citation>
    <PMID>25838374</PMID>
  </reference>
  <reference>
    <citation>Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, Dengel K, Kerr ND, Bagg A, Levine BL, June CH, Stadtmauer EA. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N Engl J Med. 2015 Sep 10;373(11):1040-7. doi: 10.1056/NEJMoa1504542.</citation>
    <PMID>26352815</PMID>
  </reference>
  <reference>
    <citation>Casucci M, Nicolis di Robilant B, Falcone L, Camisa B, Norelli M, Genovese P, Gentner B, Gullotta F, Ponzoni M, Bernardi M, Marcatti M, Saudemont A, Bordignon C, Savoldo B, Ciceri F, Naldini L, Dotti G, Bonini C, Bondanza A. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood. 2013 Nov 14;122(20):3461-72. doi: 10.1182/blood-2013-04-493361. Epub 2013 Sep 9.</citation>
    <PMID>24016461</PMID>
  </reference>
  <reference>
    <citation>Shaffer DR, Savoldo B, Yi Z, Chow KK, Kakarla S, Spencer DM, Dotti G, Wu MF, Liu H, Kenney S, Gottschalk S. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood. 2011 Apr 21;117(16):4304-14. doi: 10.1182/blood-2010-04-278218. Epub 2011 Feb 8.</citation>
    <PMID>21304103</PMID>
  </reference>
  <reference>
    <citation>Drent E, Groen RW, Noort WA, Themeli M, Lammerts van Bueren JJ, Parren PW, Kuball J, Sebestyen Z, Yuan H, de Bruijn J, van de Donk NW, Martens AC, Lokhorst HM, Mutis T. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica. 2016 May;101(5):616-25. doi: 10.3324/haematol.2015.137620. Epub 2016 Feb 8.</citation>
    <PMID>26858358</PMID>
  </reference>
  <reference>
    <citation>Drent E, Themeli M, Poels R, de Jong-Korlaar R, Yuan H, de Bruijn J, Martens ACM, Zweegman S, van de Donk NWCJ, Groen RWJ, Lokhorst HM, Mutis T. A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization. Mol Ther. 2017 Aug 2;25(8):1946-1958. doi: 10.1016/j.ymthe.2017.04.024. Epub 2017 May 13.</citation>
    <PMID>28506593</PMID>
  </reference>
  <reference>
    <citation>O'Connell FP, Pinkus JL, Pinkus GS. CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. Am J Clin Pathol. 2004 Feb;121(2):254-63.</citation>
    <PMID>14983940</PMID>
  </reference>
  <reference>
    <citation>Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, McNiece I, Lin L, Ambinder RF, Peacock C, Watkins DN, Huff CA, Jones RJ. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008 Jan 1;68(1):190-7. doi: 10.1158/0008-5472.CAN-07-3096.</citation>
    <PMID>18172311</PMID>
  </reference>
  <reference>
    <citation>Ramos CA, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O, Liu E, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Brenner MK, Heslop HE, Dotti G. Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. J Clin Invest. 2016 Jul 1;126(7):2588-96. doi: 10.1172/JCI86000. Epub 2016 Jun 6.</citation>
    <PMID>27270177</PMID>
  </reference>
  <reference>
    <citation>Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y, Rice AG, van Abbema A, Wong M, Liu G, Zhan F, Dillon M, Chen S, Rhodes S, Fuh F, Tsurushita N, Kumar S, Vexler V, Shaughnessy JD Jr, Barlogie B, van Rhee F, Hussein M, Afar DE, Williams MB. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008 May 1;14(9):2775-84. doi: 10.1158/1078-0432.CCR-07-4246.</citation>
    <PMID>18451245</PMID>
  </reference>
  <reference>
    <citation>Chu J, He S, Deng Y, Zhang J, Peng Y, Hughes T, Yi L, Kwon CH, Wang QE, Devine SM, He X, Bai XF, Hofmeister CC, Yu J. Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells. Clin Cancer Res. 2014 Aug 1;20(15):3989-4000. doi: 10.1158/1078-0432.CCR-13-2510. Epub 2014 Mar 27.</citation>
    <PMID>24677374</PMID>
  </reference>
  <reference>
    <citation>Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, Brudno JN, Stetler-Stevenson M, Feldman SA, Hansen BG, Fellowes VS, Hakim FT, Gress RE, Kochenderfer JN. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016 Sep 29;128(13):1688-700. doi: 10.1182/blood-2016-04-711903. Epub 2016 Jul 13.</citation>
    <PMID>27412889</PMID>
  </reference>
  <reference>
    <citation>Rotolo A, Caputo V, Karadimitris A. The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma. Br J Haematol. 2016 May;173(3):350-64. doi: 10.1111/bjh.13976. Epub 2016 Mar 8. Review.</citation>
    <PMID>26953076</PMID>
  </reference>
  <reference>
    <citation>Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, Gress RE, Hakim FT, Kochenderfer JN. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013 Apr 15;19(8):2048-60. doi: 10.1158/1078-0432.CCR-12-2422. Epub 2013 Jan 23.</citation>
    <PMID>23344265</PMID>
  </reference>
  <reference>
    <citation>Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, Gross JA, Greipp PR, Jelinek DF. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 2004 Jan 15;103(2):689-94. Epub 2003 Sep 25.</citation>
    <PMID>14512299</PMID>
  </reference>
  <reference>
    <citation>Ryan MC, Hering M, Peckham D, McDonagh CF, Brown L, Kim KM, Meyer DL, Zabinski RF, Grewal IS, Carter PJ. Antibody targeting of B-cell maturation antigen on malignant plasma cells. Mol Cancer Ther. 2007 Nov;6(11):3009-18.</citation>
    <PMID>18025285</PMID>
  </reference>
  <reference>
    <citation>Xu S, Lam KP. B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol Cell Biol. 2001 Jun;21(12):4067-74.</citation>
    <PMID>11359913</PMID>
  </reference>
  <reference>
    <citation>Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, Smith BD, Civin CI, Jones RJ. Characterization of clonogenic multiple myeloma cells. Blood. 2004 Mar 15;103(6):2332-6. Epub 2003 Nov 20.</citation>
    <PMID>14630803</PMID>
  </reference>
  <reference>
    <citation>Zah E, Lin MY, Silva-Benedict A, Jensen MC, Chen YY. T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells. Cancer Immunol Res. 2016 Jun;4(6):498-508. doi: 10.1158/2326-6066.CIR-15-0231. Epub 2016 Apr 8.</citation>
    <PMID>27059623</PMID>
  </reference>
  <reference>
    <citation>Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, Corder A, Schönfeld K, Koch J, Dotti G, Heslop HE, Gottschalk S, Wels WS, Baker ML, Ahmed N. TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy. Mol Ther Nucleic Acids. 2013 Jul 9;2:e105. doi: 10.1038/mtna.2013.32.</citation>
    <PMID>23839099</PMID>
  </reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 11, 2018</study_first_submitted>
  <study_first_submitted_qc>October 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2018</study_first_posted>
  <last_update_submitted>October 11, 2018</last_update_submitted>
  <last_update_submitted_qc>October 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Peng Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

